Posttest- Treatment Options for Patients with Tough-to-Treat Cholesterol and High Cardiovascular Risk: When Statins Aren’t Enough (ID: i765)
Georgia Academy of Family Physicians
Saturday, November 14, 2020

Question Title

* 1. To receive credit for participation in this activity please complete the following evaluation:

Name

Degree

Email Address

Question Title

* 2. After participating in this activity, how confident are you in the management of patients with high cholesterol?

 Very confident

 Confident

 Neutral

 Little confidence

 No confidence

Question Title

* 3. 67 yo AAF with HTN/T2DM (no prior CV events). Comes to your clinic has an LDL-C of 75 mg/dL complaining of “sore muscles” and believes she is “statin intolerant”. She states that her mom and sister also had problems with “all statin drugs”. She has only tried atorvastatin 80 mg po daily. Of the following options, what is the appropriate next step to assess whether this patient has statin intolerance?

 Diagnose her with statin intolerance and start her on a non-statin alternative

 Order genetic testing to determine if she is prone to side effects from statins

 Start her on another statin, or a lower dose of atorvastatin

 Continue with atorvastatin, 80mg, and prescribe vitamin D and coenzyme Q10

Question Title

* 4. The ORION phase 3 clinical trial program of inclisiran demonstrated the potential of its LDL-C-lowering effects in which patient population(s)?

 Homozygous FH only

 Secondary ASCVD prevention only

 Statin intolerance

 Heterozygous FH, ASCVD or an ASCVD risk equivalent

Question Title

* 5. What would you recommend for a patient with HeFH and no clinical ASCVD and LDL-C of 105 mg/dL who is taking ezetimibe, but has severe statin-associated muscle symptoms that recurred upon rechallenge with the lowest possible statin dose?

 Lipid apheresis

 Bile acid sequestrant

 PCSK9 inhibitor

 Bempedoic acid

Question Title

* 6. The approximate reduction in LDL-C demonstrated for bempedoic acid in its CLEAR phase 3 clinical trial program was:

 4-9%

 13-24%

 25-33%

 50-60%

Question Title

* 7. In a phase 2 trials, roxadustat and daprodustat demonstrated all of the following outcomes in at least one trial, except?

 Decreased ferritin

 Decreased hepcidin

 Decreased cholesterol

 Increased total iron binding capacity (TIBC)

 Increased VEGF

Question Title

* 8. What is your area of specialization?

 Cardiology

 Family Medicine

 General Practice

 Internal Medicine

 Other:____________________

Question Title

* 9. How many years have you been in practice?

 >21

 11-20

 1-10

 <1

Question Title

* 10. How many patients with high cholesterol do you manage?

 < 5

 5 to 15

 16 to 25

 26 to 35

 36 to 45

 > 45

 I do not directly provide care

Question Title

* 11. After participating in today's activity, I am now able to:

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Identify and diagnose patients with hypercholesterolemia who are statin resistant or intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and management algorithms.	Identify and diagnose patients with hypercholesterolemia who are statin resistant or intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and management algorithms. Strongly Agree	Identify and diagnose patients with hypercholesterolemia who are statin resistant or intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and management algorithms. Agree	Identify and diagnose patients with hypercholesterolemia who are statin resistant or intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and management algorithms. Neutral	Identify and diagnose patients with hypercholesterolemia who are statin resistant or intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and management algorithms. Disagree	Identify and diagnose patients with hypercholesterolemia who are statin resistant or intolerant based on past medical and familial history, adverse effects of statins, and recommended definitions and management algorithms. Strongly Disagree
Evaluate the benefits versus risks of lipid-modifying drugs based on safety and efficacy for the treatment of hypercholesterolemia in patients with elevated atherogenic cholesterol levels and statin intolerance.	Evaluate the benefits versus risks of lipid-modifying drugs based on safety and efficacy for the treatment of hypercholesterolemia in patients with elevated atherogenic cholesterol levels and statin intolerance. Strongly Agree	Evaluate the benefits versus risks of lipid-modifying drugs based on safety and efficacy for the treatment of hypercholesterolemia in patients with elevated atherogenic cholesterol levels and statin intolerance. Agree	Evaluate the benefits versus risks of lipid-modifying drugs based on safety and efficacy for the treatment of hypercholesterolemia in patients with elevated atherogenic cholesterol levels and statin intolerance. Neutral	Evaluate the benefits versus risks of lipid-modifying drugs based on safety and efficacy for the treatment of hypercholesterolemia in patients with elevated atherogenic cholesterol levels and statin intolerance. Disagree	Evaluate the benefits versus risks of lipid-modifying drugs based on safety and efficacy for the treatment of hypercholesterolemia in patients with elevated atherogenic cholesterol levels and statin intolerance. Strongly Disagree
Summarize the evidence of new and emerging lipid-modifying agents in development for the optimal treatment of statin resistant and intolerant patients.	Summarize the evidence of new and emerging lipid-modifying agents in development for the optimal treatment of statin resistant and intolerant patients. Strongly Agree	Summarize the evidence of new and emerging lipid-modifying agents in development for the optimal treatment of statin resistant and intolerant patients. Agree	Summarize the evidence of new and emerging lipid-modifying agents in development for the optimal treatment of statin resistant and intolerant patients. Neutral	Summarize the evidence of new and emerging lipid-modifying agents in development for the optimal treatment of statin resistant and intolerant patients. Disagree	Summarize the evidence of new and emerging lipid-modifying agents in development for the optimal treatment of statin resistant and intolerant patients. Strongly Disagree

Question Title

* 12. Please rate your level of agreement with the statement(s) below:

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
My opportunity for learning assessment was appropriate to the activity	My opportunity for learning assessment was appropriate to the activity Strongly Agree	My opportunity for learning assessment was appropriate to the activity Agree	My opportunity for learning assessment was appropriate to the activity Neutral	My opportunity for learning assessment was appropriate to the activity Disagree	My opportunity for learning assessment was appropriate to the activity Strongly Disagree
The content presented enhanced my current knowledge base	The content presented enhanced my current knowledge base Strongly Agree	The content presented enhanced my current knowledge base Agree	The content presented enhanced my current knowledge base Neutral	The content presented enhanced my current knowledge base Disagree	The content presented enhanced my current knowledge base Strongly Disagree
The content presented was scientifically rigorous and evidenced-based	The content presented was scientifically rigorous and evidenced-based Strongly Agree	The content presented was scientifically rigorous and evidenced-based Agree	The content presented was scientifically rigorous and evidenced-based Neutral	The content presented was scientifically rigorous and evidenced-based Disagree	The content presented was scientifically rigorous and evidenced-based Strongly Disagree
The scope, depth, and level of content were appropriate	The scope, depth, and level of content were appropriate Strongly Agree	The scope, depth, and level of content were appropriate Agree	The scope, depth, and level of content were appropriate Neutral	The scope, depth, and level of content were appropriate Disagree	The scope, depth, and level of content were appropriate Strongly Disagree
The invitation accurately conveyed the purpose and content	The invitation accurately conveyed the purpose and content Strongly Agree	The invitation accurately conveyed the purpose and content Agree	The invitation accurately conveyed the purpose and content Neutral	The invitation accurately conveyed the purpose and content Disagree	The invitation accurately conveyed the purpose and content Strongly Disagree
The activities (e.g. faculty questions/discussion, case studies) provided appropriate and effective opportunities for active learning	The activities (e.g. faculty questions/discussion, case studies) provided appropriate and effective opportunities for active learning Strongly Agree	The activities (e.g. faculty questions/discussion, case studies) provided appropriate and effective opportunities for active learning Agree	The activities (e.g. faculty questions/discussion, case studies) provided appropriate and effective opportunities for active learning Neutral	The activities (e.g. faculty questions/discussion, case studies) provided appropriate and effective opportunities for active learning Disagree	The activities (e.g. faculty questions/discussion, case studies) provided appropriate and effective opportunities for active learning Strongly Disagree
The activity promoted improvements of quality in health care	The activity promoted improvements of quality in health care Strongly Agree	The activity promoted improvements of quality in health care Agree	The activity promoted improvements of quality in health care Neutral	The activity promoted improvements of quality in health care Disagree	The activity promoted improvements of quality in health care Strongly Disagree

Question Title

* 13. Was this activity fair and balanced?

Yes

If you answered no, please explain:

Question Title

* 14. Did the activity avoid commercial bias or influence?

Yes

If you answered no, please explain:

Question Title

* 15. The faculty provided a disclosure and disclosed any off-label/investigational use of products discussed before the start of the activity.

Yes

If you answered no, please explain:

Question Title

* 16. As a result of participating in this activity, what will you do differently to improve the care of your patients?

Gained new strategies, skills or information that I can apply to my area of practice

Need more information before I can implement new strategies/skills/information into my practice behavior

Will not change my practice, as my current practice is consistent with information presented

Will not change my practice, as I do not agree with the information presented

Question Title

* 17. If you gained new strategies, skills, and/or information that you plan to implement into your practice, what types of changes do you plan to implement?

Posttest- Treatment Options for Patients with Tough-to-Treat Cholesterol and High Cardiovascular Risk: When Statins Aren’t Enough (ID: i765)
Georgia Academy of Family Physicians
Saturday, November 14, 2020

Question Title

* 1. To receive credit for participation in this activity please complete the following evaluation:

Question Title

* 2. After participating in this activity, how confident are you in the management of patients with high cholesterol?

Question Title

Question Title

* 4. The ORION phase 3 clinical trial program of inclisiran demonstrated the potential of its LDL-C-lowering effects in which patient population(s)?

Question Title

* 5. What would you recommend for a patient with HeFH and no clinical ASCVD and LDL-C of 105 mg/dL who is taking ezetimibe, but has severe statin-associated muscle symptoms that recurred upon rechallenge with the lowest possible statin dose?

Question Title

* 6. The approximate reduction in LDL-C demonstrated for bempedoic acid in its CLEAR phase 3 clinical trial program was:

Question Title

* 7. In a phase 2 trials, roxadustat and daprodustat demonstrated all of the following outcomes in at least one trial, except?

Question Title

* 8. What is your area of specialization?

Question Title

* 9. How many years have you been in practice?

Question Title

* 10. How many patients with high cholesterol do you manage?

Question Title

* 11. After participating in today's activity, I am now able to:

Question Title

* 12. Please rate your level of agreement with the statement(s) below:

Question Title

* 13. Was this activity fair and balanced?

Question Title

* 14. Did the activity avoid commercial bias or influence?

Question Title

* 15. The faculty provided a disclosure and disclosed any off-label/investigational use of products discussed before the start of the activity.

Question Title

* 16. As a result of participating in this activity, what will you do differently to improve the care of your patients?

Question Title

* 17. If you gained new strategies, skills, and/or information that you plan to implement into your practice, what types of changes do you plan to implement?

Question Title

* 18. What barriers do you see to implementing these changes in your practice?

Question Title

* 19. Please provide any additional comments related to the activity in the space below.

Posttest- Treatment Options for Patients with Tough-to-Treat Cholesterol and High Cardiovascular Risk: When Statins Aren’t Enough (ID: i765) Georgia Academy of Family Physicians Saturday, November 14, 2020

Question Title

* 1. To receive credit for participation in this activity please complete the following evaluation:

Question Title

* 2. After participating in this activity, how confident are you in the management of patients with high cholesterol?

Question Title

Question Title

* 4. The ORION phase 3 clinical trial program of inclisiran demonstrated the potential of its LDL-C-lowering effects in which patient population(s)?

Question Title

* 5. What would you recommend for a patient with HeFH and no clinical ASCVD and LDL-C of 105 mg/dL who is taking ezetimibe, but has severe statin-associated muscle symptoms that recurred upon rechallenge with the lowest possible statin dose?

Question Title

* 6. The approximate reduction in LDL-C demonstrated for bempedoic acid in its CLEAR phase 3 clinical trial program was:

Question Title

* 7. In a phase 2 trials, roxadustat and daprodustat demonstrated all of the following outcomes in at least one trial, except?

Question Title

* 8. What is your area of specialization?

Question Title

* 9. How many years have you been in practice?

Question Title

* 10. How many patients with high cholesterol do you manage?

Question Title

* 11. After participating in today's activity, I am now able to:

Question Title

* 12. Please rate your level of agreement with the statement(s) below:

Question Title

* 13. Was this activity fair and balanced?

Question Title

* 14. Did the activity avoid commercial bias or influence?

Question Title

* 15. The faculty provided a disclosure and disclosed any off-label/investigational use of products discussed before the start of the activity.

Question Title

* 16. As a result of participating in this activity, what will you do differently to improve the care of your patients?

Question Title

* 17. If you gained new strategies, skills, and/or information that you plan to implement into your practice, what types of changes do you plan to implement?

Question Title

* 18. What barriers do you see to implementing these changes in your practice?

Question Title

* 19. Please provide any additional comments related to the activity in the space below.

Posttest- Treatment Options for Patients with Tough-to-Treat Cholesterol and High Cardiovascular Risk: When Statins Aren’t Enough (ID: i765)
Georgia Academy of Family Physicians
Saturday, November 14, 2020